According to available data in non-surgical patients, early treatment response (13 months) to the weight loss drug seems to be a good predictor of long-term weight maintenance [31,32,33,34]
Gastrointestinal side effects may worsen temporarily after the dose increase but typically stabilize within a week
As discussed above, a study of the enterogastrone effects of GLP-1 and PYY in dogs, where the GLP-1 receptor antagonist exendin 939 was incapable of blocking the inhibitory actions of GLP-1 (71), suggested that another receptor was involved
The medication that works for someone else might not work for you
So for GLP-1s, we know that there is a lot of benefit in terms of reduced events and deaths for people who have heart diseasetheir risk of heart attack and stroke is decreased
Both are shown in animal models to be particularly adept at suppressing TNF-alpha, a cytokine that is heavily linked with inflammatory bowel disease [16, 17, 18]